AGL 31.35 Increased By ▲ 0.15 (0.48%)
AIRLINK 143.00 Increased By ▲ 0.30 (0.21%)
BOP 5.12 Increased By ▲ 0.04 (0.79%)
CNERGY 4.11 Increased By ▲ 0.07 (1.73%)
DCL 9.49 Decreased By ▼ -0.21 (-2.16%)
DFML 49.51 Decreased By ▼ -0.69 (-1.37%)
DGKC 79.10 Decreased By ▼ -0.40 (-0.5%)
FCCL 22.75 Decreased By ▼ -0.30 (-1.3%)
FFBL 46.78 Increased By ▲ 0.68 (1.48%)
FFL 9.57 Increased By ▲ 0.52 (5.75%)
HUBC 153.49 Decreased By ▼ -0.01 (-0.01%)
HUMNL 11.29 Decreased By ▼ -0.18 (-1.57%)
KEL 4.17 Increased By ▲ 0.03 (0.72%)
KOSM 9.26 Decreased By ▼ -1.01 (-9.83%)
MLCF 33.30 Decreased By ▼ -0.30 (-0.89%)
NBP 58.70 Increased By ▲ 1.85 (3.25%)
OGDC 136.75 Decreased By ▼ -0.50 (-0.36%)
PAEL 25.88 Increased By ▲ 1.43 (5.85%)
PIBTL 6.05 Increased By ▲ 0.08 (1.34%)
PPL 112.35 Decreased By ▼ -0.65 (-0.58%)
PRL 24.38 Increased By ▲ 0.03 (0.12%)
PTC 11.88 Decreased By ▼ -0.07 (-0.59%)
SEARL 57.40 Decreased By ▼ -0.36 (-0.62%)
TELE 7.77 Increased By ▲ 0.17 (2.24%)
TOMCL 41.99 Increased By ▲ 0.11 (0.26%)
TPLP 8.49 Decreased By ▼ -0.16 (-1.85%)
TREET 15.23 Increased By ▲ 0.13 (0.86%)
TRG 51.50 Decreased By ▼ -0.95 (-1.81%)
UNITY 28.00 Increased By ▲ 0.14 (0.5%)
WTL 1.42 Increased By ▲ 0.08 (5.97%)
BR100 8,340 Decreased By -5.8 (-0.07%)
BR30 26,956 Increased By 47.9 (0.18%)
KSE100 78,898 Increased By 34.4 (0.04%)
KSE30 25,008 Decreased By -18.2 (-0.07%)

BEIJING: Chinese authorities summoned officials of AstraZeneca China regarding an investigation of suspected medical insurance fraud by the company’s employees, the National Healthcare Security Administration (NHSA) said on Saturday.

The regulator of the state medical insurance fund said authorities ordered the arrest of all suspects, but did not give details of the suspected violations or the size of funds involved.

It demanded that AstraZeneca China close loopholes in supervision of marketing activities, the NHSA added.

In a statement on Friday, the company said some employees in the southern city of Shenzhen had altered or participated in altering patients’ testing reports, and were suspected of medical insurance fraud.

The NHSA and public security ministry held a meeting with company officials in December to brief them on the investigation, it added.

“AstraZeneca China takes such employee misconduct seriously and welcomes the recommendations by the NHSA and MOPS,” it said.

An AstraZeneca spokesperson said all employees involved in the Shenzhen case were Chinese nationals.

Comments

Comments are closed.